Stellanova Therapeutics
Conquering Cancer
Conquering Cancer
Stellanova Therapeutics is a biotechnology startup with a mission to conquer cancer by developing pioneering cancer therapies. Founded in 2019 based on research from Dr. Rosa Hwang’s lab at MD Anderson Cancer Center, the company is focused on targeting cancer-associated fibroblasts (CAFs) and their interactions within the tumor microenvironment. Their research, particularly on stellate cells present in pancreatic cancer, has shown potential in directly combating cancer and increasing the vulnerability of tumor cells to traditional therapeutic approaches like chemotherapy and immunotherapy.
The name Stellanova signifies “new star,” reflecting the company's ambition to establish an entirely novel approach to cancer treatment. Its latest milestone was a $15.50M Series A investment on 03 June 2021 led by Sporos Bioventures. The company operates in the Biotechnology and Health Care industries and is headquartered in the United States.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $15.50M | 1 |
|
03 Jun 2021 |
No recent news or press coverage available for Stellanova Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
